Evonik Industries (XTRA:EVK) reported second quarter 2026 results with sales of €3,893 million and net income of €84 million. Earnings per share from continuing operations were €0.18 for the quarter.
See our latest analysis for Evonik Industries.
The latest quarterly update from Evonik Industries comes after a strong run in the share price, with a year to date share price return of 34.26% and a 1 year total shareholder return of 14.23%. This suggests momentum has picked up recently despite a weaker 5 year total shareholder return that declined 17.88%.
If you are using these results as a prompt to widen your watchlist, this is a good moment to look at other ideas through the Simply Wall St screener and check out 104 top founder-led companies.
Evonik Industries now has stronger sales but lower recent earnings, and a share price that has already moved up sharply in 2026. The business looks solid. The real puzzle is whether that strength is already fully in the price.
Most Popular Narrative: 1% Overvalued
Evonik Industries closed at €17.87, slightly above the most followed fair value estimate of €17.78, which hinges on a detailed long term earnings and margin story.
Strategic cost optimization programs, including significant headcount reductions and site closures (notably in Silica), are expected to lower operating costs and support net margin expansion throughout 2025 as savings become fully visible by year end.
Want to see what sits behind that margin uplift story? The narrative focuses on higher profitability, steadier cash generation, and a richer earnings multiple. The specific revenue and earnings paths might surprise you.
Result: Fair Value of €17.78 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks for Evonik Industries if weak demand in key end markets persists or if exposure to lower margin commodity chemicals slows progress.
Find out about the key risks to this Evonik Industries narrative.
Another View On Evonik Industries’ Valuation
While the analyst narrative points to Evonik Industries trading roughly in line with a €17.78 fair value based on earnings and target prices, the Simply Wall St DCF model paints a very different picture. On that framework, the current share price of €17.87 sits well below an estimated future cash flow value of €71.03, which implies a very large gap.
This sort of split between earnings based pricing and cash flow based value forces a choice about which assumptions you trust more. Are the cash flows too optimistic, or are short term earnings and multiples missing something longer term?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Evonik Industries for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 248 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals around Evonik Industries can make the picture feel unclear, so move quickly to review the full risk and reward balance for yourself with 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Evonik Industries?
Do not stop your research with Evonik Industries. Broaden your watchlist now so you are not late to the next opportunity that fits your approach.
- Zero in on quality at a fair price and scan through 248 high quality undervalued stocks that combine solid fundamentals with appealing valuations.
- Strengthen the defensive side of your portfolio by reviewing 307 resilient stocks with low risk scores that score well on resilience and stability.
- Get ahead of the crowd by checking a screener containing 548 high quality undiscovered gems before they hit more investors' radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com